<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774747</url>
  </required_header>
  <id_info>
    <org_study_id>D7750090</org_study_id>
    <nct_id>NCT01774747</nct_id>
  </id_info>
  <brief_title>A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder</brief_title>
  <acronym>MAD</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, placebo-controlled, multiple ascending oral dose evaluation of the safety,&#xD;
      tolerability, and pharmacokinetics of DSP 1053 and its metabolites in healthy subjects and in&#xD;
      subjects with major depressive disorder&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be conducted at a single site as a double-blind, placebo-controlled, mulitple&#xD;
      ascending oral doses evaluation of the safety, tolerability, and pharmacokinetics of DSP-1053&#xD;
      and its metabolites in healthy subjects with Major depressive disorder after the minimumally&#xD;
      intolerated dose is reached in healthy subjects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This program was terminated for financial reasons&#xD;
  </why_stopped>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To reach minimumally intolerable dose based on stopping criteria</measure>
    <time_frame>14 days</time_frame>
    <description>At least 50% of subjects within a cohort at dose level experience multiple moderate drug related adverse events or one severe drug-related adverse event&#xD;
one drug related serious adverse event within a cohort at dose level&#xD;
seizure of any severity or seriousness is observed in a subject who received DSP-1053&#xD;
Mean plasma DSR_22898 Cmax greater or equal to 32ng/ml for a cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic relationship based on serotonin transporter occupancy of DSP-1053 following multiple oral doses of DSP-1053 in healthy subjects and major depressive disorder subjects</measure>
    <time_frame>14 days</time_frame>
    <description>Measurement of inhibition of active [H]-5HT transport in cells expressing the human serotonin transporter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize exposure of DSP-1053 and its metabolites (AUC, Cmax and Tmax) after multiple ascending dose of DSP-1053</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DSP-1053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-1053</intervention_name>
    <description>DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
    <arm_group_label>DSP-1053</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days</description>
    <arm_group_label>DSP-1053</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Subjects:&#xD;
&#xD;
        Be able to understand and willing to sign the Informed Consent Form, and capable of&#xD;
        providing written authorization for use and disclosure of protected health information per&#xD;
        requirements of 45 Code of Federal Regulations (CFR) 164.508 (Health Information&#xD;
        Portability and Accountability Act [HIPAA]).&#xD;
&#xD;
        Be healthy male or female subjects between 18 and 50 years of age (inclusive). Have a BMI&#xD;
        18 and 33 kg/m2. Have no clinically relevant abnormal laboratory values at screening and&#xD;
        Day -1.&#xD;
&#xD;
        Have no clinically relevant findings from vital sign measurements at screening and&#xD;
        check-in.&#xD;
&#xD;
        Have no clinically relevant findings from physical examination at screening and check in.&#xD;
&#xD;
        Have a negative urine drug of abuse test (cannabinoids, barbiturates, cocaine, opiates,&#xD;
        benzodiazepines, phencyclidine, and methadone) and negative cotinine test at screening and&#xD;
        check in.&#xD;
&#xD;
        Have a negative alcohol breath test at screening and check in. Have a negative Hepatitis B&#xD;
        surface antigen, Hepatitis C antibody, and human immunodeficiency virus (HIV) antibody&#xD;
        tests at screening.&#xD;
&#xD;
        Have normal hepatic function [aspartate transaminase (AST), bilirubin, and alanine&#xD;
        transaminase (ALT)] and renal function (creatinine clearance greater than 80 mL/min as&#xD;
        assessed by Cockcroft Gault equation using serum creatinine) at screening and Day 1.&#xD;
&#xD;
        Be females who are of childbearing potential:&#xD;
&#xD;
        have a negative serum hCG pregnancy test at screening and Day -1; willing to not breastfeed&#xD;
        from Day -5 until 90 days after discharge from the study site;&#xD;
&#xD;
        Be females who are:&#xD;
&#xD;
        unable to have children (eg, post menopausal, tubal ligation, hysterectomy) OR willing to&#xD;
        remain abstinent (not engage in sexual intercourse) from check in until 90 days after&#xD;
        discharge from the study site.&#xD;
&#xD;
        OR willing to use an effective method of double-barrier birth control (eg, partner using&#xD;
        condom and female using diaphragm, contraceptive sponge, spermicide, or intrauterine&#xD;
        device) from check-in until 90 days after discharge from the study site.&#xD;
&#xD;
        Be males who:&#xD;
&#xD;
        are sterile or willing to remain sexually abstinent or use an effective method of birth&#xD;
        control (eg, condom) from check-in until 90 days after discharge from the study site.&#xD;
&#xD;
        AND agree not to donate sperm during the study and for 90 days after discharge from the&#xD;
        study site.&#xD;
&#xD;
        Refrain from strenuous physical activity from 48 hours prior to check-in until discharge&#xD;
        from the study site.&#xD;
&#xD;
        Agree to remain housed at the study site for the clinical confinement of study and return&#xD;
        for any visits required for additional safety or PK assessments.&#xD;
&#xD;
        Agree to consume study meals per protocol.&#xD;
&#xD;
        Subjects with MDD:&#xD;
&#xD;
        In addition to inclusion criteria mentioned above for healthy subjects, the following&#xD;
        inclusion criteria will be applied to subjects with MDD:&#xD;
&#xD;
        Have the diagnosis of MDD as defined by the Diagnostic and Statistical Manual of Mental&#xD;
        Disorders Fourth Edition; Text Revision (DSM IV TR) criteria and confirmed by the Mini&#xD;
        International Neuropsychiatric Interview (MINI) diagnostic interview. This diagnosis will&#xD;
        be confirmed by a psychiatrist or psychologist. The diagnosis should be supplemented (when&#xD;
        possible) by confirmation of chart records or by a discussion with a treating healthcare&#xD;
        professional or reliable informant. Diagnosis made by a psychologist must be reviewed by a&#xD;
        psychiatrist.&#xD;
&#xD;
        The subjects' current major depressive episode must be â‰¥ 4 weeks and &lt; 2 years in duration.&#xD;
&#xD;
        Are able to wash-out from prior antidepressant therapies by Day -1, are able to forego&#xD;
        psychotherapy from Day -1 through Day 10, inclusive, and are deemed clinically stable by&#xD;
        PI's assessment.&#xD;
&#xD;
        May have a comorbid anxiety disorder such as generalized anxiety disorder (GAD) or social&#xD;
        phobia but not obsessive compulsive disorder (OCD) as long as the comorbid anxiety disorder&#xD;
        is not the major source of impairment.&#xD;
&#xD;
        Have a stable living arrangement for at least 3 months prior to check in and agree to&#xD;
        return to a similar living arrangement after discharge. This criterion is not meant to&#xD;
        exclude subjects who have temporarily left a stable living environment. Such subjects&#xD;
        remain eligible to participate in this study. Chronically homeless subjects should not be&#xD;
        enrolled. The Medical Monitor should be consulted for individual cases as needed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Healthy Subjects&#xD;
&#xD;
        Significant history or clinical manifestations of any acute or chronic condition that in&#xD;
        the opinion of the PI, would limit the subject's ability to complete and/or participate in&#xD;
        the study:&#xD;
&#xD;
        metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal,&#xD;
        urological, neurological, or psychiatric disorders; drug hypersensitivity; stomach or&#xD;
        intestinal surgery or resection that would potentially alter absorption and/or excretion of&#xD;
        orally administered drugs (appendectomy, hernia repair, and/or cholecystectomy will be&#xD;
        allowed at the discretion of the PI); abnormal ECG, which, in the PI's opinion, is&#xD;
        clinically significant; known or suspected alcohol or substance abuse/ dependence within&#xD;
        one year prior to check in; movement disorders including tremor; lifetime or family history&#xD;
        of seizures or a febrile seizure. Poor peripheral venous access. Does not tolerate&#xD;
        venipuncture. Donation of blood from 28 days prior to screening through study completion,&#xD;
        inclusive.&#xD;
&#xD;
        Receipt of blood products within 2 months prior to check in. Any acute or chronic condition&#xD;
        that, in the opinion of the PI, would limit the subject's ability to complete and/or&#xD;
        participate in this clinical study.&#xD;
&#xD;
        Female subjects with menstrual dysfunction. Considered by the PI to be at imminent risk of&#xD;
        suicide or injury to self, others, or property.&#xD;
&#xD;
        Subject answers &quot;yes&quot; to &quot;Suicidal Ideation&quot; Items 4 or 5 on the CSSRS at screening.&#xD;
&#xD;
        Subjects who, by history, have smoked or used tobacco products within 60 days from&#xD;
        screening until study follow up.&#xD;
&#xD;
        Consumption of food or beverages containing alcohol, grapefruit, or caffeine within 72&#xD;
        hours prior to check in and until discharge from the study site, unless deemed acceptable&#xD;
        by the PI.&#xD;
&#xD;
        Participation in any other investigational study drug trial in which receipt of an&#xD;
        investigational study drug occurred within 5 half lives or 3 months prior to check-in,&#xD;
        whichever is longer.&#xD;
&#xD;
        Taken any drug(s) known to be clinically relevant cytochrome P450 2D6 (CYP2D6), or&#xD;
        cytochrome P450 3A4 (CYP3A4) inhibitors or inducers within 28 days prior to the first DSP&#xD;
        1053 dose and during the study conduct through follow up.&#xD;
&#xD;
        Taken any antihistamines within 14 days prior to check-in and during the study. Family&#xD;
        history of prolonged QT interval (QTc) prolongation. Subjects, who by history, are at any&#xD;
        risk for bleeding or have abnormal prothrombin values or currently use of anticoagulant&#xD;
        treatment (such as warfarin) Clinically important folic acid or B12 abnormalities detected&#xD;
        within 3 months before screening.&#xD;
&#xD;
        Use of any prescription medications/products within 14 days prior to check in unless deemed&#xD;
        acceptable by the PI.&#xD;
&#xD;
        Subjects with MDD&#xD;
&#xD;
        Except for Exclusion Criterion 18 mentioned above for healthy subjects all exclusion&#xD;
        criteria will be applied and in addition the following exclusion criteria will be applied&#xD;
        to subjects with MDD:&#xD;
&#xD;
        History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, eating&#xD;
        disorder, or obsessive compulsive disorder.&#xD;
&#xD;
        Any current Axis I disorder other than major depressive disorder which is the focus of&#xD;
        treatment.&#xD;
&#xD;
        Substance or alcohol abuse in the last 3 months or substance or alcohol dependence in the&#xD;
        last 12 months.&#xD;
&#xD;
        Concomitant psychotropic medication, including herbals. Significant risk of violent&#xD;
        behavior or a significant risk of suicidal behavior based on history or in the PI's&#xD;
        judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, DSP-1053</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

